Stock Screener App

Frei -

Installieren

0.9622

10.92% 0.0947

after-market

Handel nachbörslich: .98 0.0178 +1.85%

Citius Pharmaceuticals Inc (CTXR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CTXR? Forum Prognose Aktiensplit

Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten

CTXR: Citius Pharmaceuticals Receives Consistent 'Buy' Rating fr - GuruFocus

CTXR: Citius Pharmaceuticals Receives Consistent 'Buy' Rating from D. Boral Capital | CTXR Stock News - GuruFocus

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - BioSpace

Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks

Citius Oncology reports positive phase 1 trial data for LYMPHIR - Investing.com India

Market Review: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Yahoo Finance

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma - BioSpace

Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks

Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks

Citius Pharmaceuticals subsidiary reports 86% ORR, 57% CR with LYMPHIR prior to CAR‑T in high‑risk DLBCL - TradingView

Citius Oncology (Nasdaq: CTXR) reports encouraging early LYMPHIR CAR-T combo results - Stock Titan

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma – Company Announcement - Financial Times

CTXR Should I Buy - Intellectia AI

Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Citius Pharmaceuticals CEO Leonard Mazur pursues growth through regulatory partnerships and rare disease therapies - Traders Union

CTXR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Movement Recap: Is Citius Pharmaceuticals Inc benefiting from interest rate changesJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn

Citius Pharmaceuticals Secures $3.8M Via Net Operating Loss Program - New Jersey Business Magazine

Citius Pharmaceuticals Secures $3.8 Million Through New Jersey Economic Development Program - citybiz

Citius Pharmaceuticals (CTXR) Secures $3.8M Through NJ Tax Progr - GuruFocus

Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program - PR Newswire

Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar - Finviz

Market Pulse: Can Citius Pharmaceuticals Inc lead its sector in growthJuly 2025 Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn

Resistance Check: Can GRNQ maintain sales growthWeekly Market Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn

Patterns Watch: Will USAC outperform small cap indexesWeekly Loss Report & Reliable Breakout Stock Forecasts - baoquankhu1.vn

Activity Recap: How does USBPRA perform in inflationary periodsBull Run & Weekly Momentum Stock Picks - baoquankhu1.vn

Analyst Downgrade: Is NVGS forming bullish engulfing patternsMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn

Leonard Mazur: The Adventures of a Serial Entrepreneur - Pharmaceutical Executive

Dip Buying: Will Citius Pharmaceuticals Inc benefit from rate cutsJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn

CVI and Heights disclose 9.9% Citius Pharmaceuticals (CTXR) stake - Stock Titan

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - marketscreener.com

FOMO Trade: Is now the right time to enter MAPSMarket Growth Summary & Weekly Momentum Picks - baoquankhu1.vn

Can Citius Pharmaceuticals Inc. stock continue upward trendWall Street Watch & Free High Return Stock Watch Alerts - mfd.ru

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ (PR Newswire) - Aktiellt

Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal - Indian Pharma Post

Citius Oncology inks exclusive European distribution pact with Uniphar - MSN

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - The Malaysian Reserve

Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know - Benzinga

Citius Pharmaceuticals Posts First Revenue Amid Listing Risk - TipRanks

Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

CTXR: First revenue of $3.9M from LYMPHIR launch, narrowing net loss and strong pipeline progress - TradingView

Citius Pharmaceuticals, Inc. SEC 10-Q Report - TradingView

Citius Pharmaceuticals reports first revenue of $3.9 mln - TradingView

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PR Newswire

Risk Check: Should you buy the dip on ImmuCell CorporationWeekly Trend Summary & Precise Swing Trade Alerts - baoquankhu1.vn

Citius Oncology Signs Exclusive Distribution Agreement with Uniphar - Intellectia AI

Market Review: Is Citius Pharmaceuticals Inc a cyclical or defensive stockPortfolio Performance Report & Safe Swing Trade Setup Alerts - baoquankhu1.vn

Analysts Expect Breakeven For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Before Long - simplywall.st

Does Citius Pharmaceuticals Inc. align with a passive investing strategyTrade Volume Report & Daily Technical Forecast Reports - mfd.ru

Citius Oncology and Uniphar sign European distribution deal for Lymphir - Yahoo Finance

Aug PostEarnings: Is IMRN subject to activist investor interest2025 Historical Comparison & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar - Finviz

Citius Oncology Expands International Distribution of LYMPHIR™ t - GuruFocus

Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - PR Newswire

Is Citius Pharmaceuticals Inc. stock positioned well for digital economy2025 Performance Recap & Daily Entry Point Trade Alerts - mfd.ru

What is the earnings history of Citius Pharmaceuticals IncJuly 2025 Trends & Low Drawdown Investment Ideas - baoquankhu1.vn

Risk Check: What is Citius Pharmaceuticals Incs 5 year growth outlookWeekly Profit Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn

VIX Spike: Is Citius Pharmaceuticals Inc a potential multi baggerJuly 2025 WrapUp & Smart Allocation Stock Tips - baoquankhu1.vn

Weekly Earnings: Can Howard Hughes Holdings Inc deliver consistent EPS growthEarnings Overview Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn

Citius Pharmaceuticals announces registered direct offering of $15.8 million - MSN

Geopolitics Watch: Is Citius Pharmaceuticals Inc benefiting from interest rate changesTrade Performance Summary & Short-Term Trading Alerts - baoquankhu1.vn

What technical charts say about Citius Pharmaceuticals Inc. stock2025 Earnings Surprises & Weekly Top Stock Performers List - bollywoodhelpline.com

Setup Watch: Whats next for VGASW stock2025 Market Sentiment & Safe Swing Trade Setup Alerts - baoquankhu1.vn

Published on: 2026-01-13 01:39:15 - ulpravda.ru

Can Citius Pharmaceuticals Inc. stock attract ESG capital inflowsEarnings Performance Report & Stepwise Trade Signal Implementation - ulpravda.ru

Will Citius Pharmaceuticals Inc. (47N0) stock outperform Dow Jones2025 Geopolitical Influence & Entry and Exit Point Strategies - Улправда

What hedge fund moves indicate for Citius Pharmaceuticals Inc. (47N0) stockShare Buyback & Stepwise Trade Signal Implementation - ulpravda.ru

RPRX

$45.65

0.48%

ROIV

$28.06

1.72%

MRNA

$52.56

1.55%

BNTX

$91.19

1.21%

INSM

$139.50

0.01%

ONC

$284.05

0.44%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters